Entrada Therapeutics

Entrada Therapeutics is a biotechnology company focused on developing a new class of intracellular therapeutics. They have developed a proprietary platform called EEV™ (Endosomal Escape Vehicle), which allows for the efficient delivery of various therapeutics into cells. The platform addresses the challenge of delivering drugs into cells while evading the body’s natural clearing systems, potentially enabling treatment for a wide range of previously undruggable targets.

Entrada's mission is to treat devastating diseases with their intracellular therapeutics. They have a diverse and expanding pipeline of programs spanning discovery to clinical-stage development, with a focus on neuromuscular diseases such as Duchenne Muscular Dystrophy. Entrada is also exploring the potential of their EEV™ Platform for immunological, ocular, and metabolic diseases. Their commitment to diversity, equity, and inclusion is reflected in their DREAMS grant program, which supports organizations working to improve healthcare accessibility within the Duchenne community.

Entrada Therapeutics offers a flexible work environment that supports a range of needs. They provide commuter benefits to cover expenses no matter how employees get to work, subsidized lunches and snacks to make it easy to stay fueled at the office, and a mobile stipend to help employees stay connected. Additionally, they offer parental leave and celebrate both personal and professional milestones, showcasing their commitment to supporting employees through different life stages.

Entrada Therapeutics offers a comprehensive benefits package designed to support employees at all stages of life. They provide a $500 wellness benefit, subsidized lunches and snacks, commuter benefits up to $300, and opportunities for professional development. They also offer a mobile stipend to help employees stay connected, company swag, parental leave, and celebrate both personal and professional milestones.

Entrada Therapeutics is a biotechnology company committed to developing a new class of intracellular therapeutics to treat devastating diseases. Their proprietary EEV™ Platform is designed to deliver therapies directly into cells, enabling them to target previously inaccessible disease-causing targets. Entrada is focused on developing innovative treatments for a range of diseases including Duchenne muscular dystrophy, myotonic dystrophy type 1, Pompe disease, and other conditions. They are dedicated to improving patient outcomes and creating a more equitable and inclusive healthcare system.

Entrada Therapeutics fosters a culture of relentless pursuit of developing therapies for patients, driven by a passion for science and a genuine care for both patients and one another. They value intellectual curiosity, creativity, and collaboration, creating an environment where everyone feels valued and can contribute their unique perspectives. This dedication to inclusion and diversity extends beyond their internal team, as they actively partner with organizations to challenge the status quo and improve the future for all.

Entrada Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace environment where all employees feel valued and empowered to contribute. They believe that embracing different experiences and perspectives fuels innovation and drives success. The company actively partners with organizations across Boston, Cambridge, and the biotech sector to create a welcoming and supportive environment where everyone's voice is heard and every individual belongs. They are dedicated to addressing disparities and championing inclusivity within the Duchenne muscular dystrophy community through their annual DREAMS grant program, which supports organizations dedicated to improving access to care and resources for underserved populations.